Literature DB >> 8962133

Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility.

W Weng1, J L Breslow.   

Abstract

Apolipoprotein (apo) A-II is the second most abundant apolipoprotein in high density lipoprotein (HDL). To study its role in lipoprotein metabolism and atherosclerosis susceptibility, apo A-II knockout mice were created. Homozygous knockout mice had 67% and 52% reductions in HDL cholesterol levels in the fasted and fed states, respectively, and HDL particle size was reduced. Metabolic turnover studies revealed the HDL decrease to be due to both decreased HDL cholesterol ester and apo A-I transport rate and increased HDL cholesterol ester and apo A-I fractional catabolic rate. The apo A-II deficiency trait was bred onto the atherosclerosis-prone apo E-deficient background, which resulted in a surprising 66% decrease in cholesterol levels due primarily to decreased atherogenic lipoprotein remnant particles. Metabolic turnover studies indicated increased remnant clearance in the absence of apo A-II. Finally, apo A-II deficiency was associated with lower free fatty acid, glucose, and insulin levels, suggesting an insulin hypersensitivity state. In summary, apo A-II plays a complex role in lipoprotein metabolism, with some antiatherogenic properties such as the maintenance of a stable HDL pool, and other proatherogenic properties such as decreasing clearance of atherogenic lipoprotein remnants and promotion of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8962133      PMCID: PMC26214          DOI: 10.1073/pnas.93.25.14788

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Nondenaturing polyacrylamide gradient gel electrophoresis.

Authors:  A V Nichols; R M Krauss; T A Musliner
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

2.  Apolipoprotein A-I containing lipoproteins in coronary artery disease.

Authors:  P Puchois; A Kandoussi; P Fievet; J L Fourrier; M Bertrand; E Koren; J C Fruchart
Journal:  Atherosclerosis       Date:  1987-11       Impact factor: 5.162

3.  In vitro modulation of the apolipoprotein composition of high density lipoprotein. Displacement of apolipoprotein A-I from high density lipoprotein by apolipoprotein A-II.

Authors:  P A Lagocki; A M Scanu
Journal:  J Biol Chem       Date:  1980-04-25       Impact factor: 5.157

4.  Characterization of human high-density lipoproteins by gradient gel electrophoresis.

Authors:  P J Blanche; E L Gong; T M Forte; A V Nichols
Journal:  Biochim Biophys Acta       Date:  1981-09-24

5.  Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production.

Authors:  A S Plump; S K Erickson; W Weng; J S Partin; J L Breslow; D L Williams
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

6.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

Review 7.  Role of insulin resistance in human disease (syndrome X): an expanded definition.

Authors:  G M Reaven
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

8.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

Authors:  A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

9.  Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.

Authors:  J R Schultz; J G Verstuyft; E L Gong; A V Nichols; E M Rubin
Journal:  Nature       Date:  1993-10-21       Impact factor: 49.962

10.  Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice.

Authors:  C C Hedrick; L W Castellani; C H Warden; D L Puppione; A J Lusis
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

View more
  39 in total

1.  Naturally occurring variant of mouse apolipoprotein A-I alters the lipid and HDL association properties of the protein.

Authors:  Timothy J Sontag; Ronald Carnemolla; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2012-03-08       Impact factor: 5.922

Review 2.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

3.  A composite computational model of liver glucose homeostasis. II. Exploring system behaviour.

Authors:  T Sumner; J Hetherington; R M Seymour; L Li; M Varela Rey; S Yamaji; P Saffrey; O Margoninski; I D L Bogle; A Finkelstein; A Warner
Journal:  J R Soc Interface       Date:  2012-02-08       Impact factor: 4.118

Review 4.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

5.  Plasma carboxyl ester lipase activity modulates apolipoprotein B-containing lipoprotein metabolism in a transgenic mouse model.

Authors:  Ling Li; Wei Weng; Earl H Harrison; Edward A Fisher
Journal:  Metabolism       Date:  2008-10       Impact factor: 8.694

6.  Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.

Authors:  G P Hayhurst; Y H Lee; G Lambert; J M Ward; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

7.  Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol.

Authors:  Laxman Yetukuri; Sanni Söderlund; Artturi Koivuniemi; Tuulikki Seppänen-Laakso; Perttu S Niemelä; Marja Hyvönen; Marja-Riitta Taskinen; Ilpo Vattulainen; Matti Jauhiainen; Matej Oresic
Journal:  J Lipid Res       Date:  2010-04-29       Impact factor: 5.922

8.  C57BL/6J mouse apolipoprotein A2 gene is deterministic for apnea.

Authors:  Carl B Gillombardo; Rebecca Darrah; Thomas E Dick; Michael Moore; Nathan Kong; Michael J Decker; Fang Han; Motoo Yamauchi; Mathias Dutschmann; Sausan Azzam; Kingman P Strohl
Journal:  Respir Physiol Neurobiol       Date:  2016-10-15       Impact factor: 1.931

9.  Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Authors:  Yao Wang; Manabu Niimi; Kazutoshi Nishijima; Ahmed Bilal Waqar; Ying Yu; Tomonari Koike; Shuji Kitajima; Enqi Liu; Tomohiro Inoue; Masayuki Kohashi; Yuka Keyamura; Tomohiro Yoshikawa; Jifeng Zhang; Loretta Ma; Xiaohui Zha; Teruo Watanabe; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

Review 10.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.